2023-04-17 17:06:41
To clarify the population about the use of the Oxford-AstraZeneca vaccine against Covid-19, the Ministry of Health released last week information about the current recommendation.
As the folder, since December the vaccine is indicated for people from 40 years, according to the most recent scientific evidence. That is, it continues to be applied in the country.
The recommendation is reinforced after the circulation of false news on social networks that said that a technical note from the Ministry of Health, released in December, reported that the immunizer would have caused thrombosis in people aged over 40 years, especially among women. And, therefore, its application would no longer be authorized.
“The Ministry of Health reinforces that all vaccines offered to the population are safe, effective and approved by the National Health Surveillance Agency (Anvisa). of the sector and new scientific evidence on the subject, discussed within the scope of the Technical Advisory Board on Immunizations.”
According to the ministry, the Oxford-AstraZeneca vaccine, developed at the beginning of the pandemic and produced by the Oswaldo Cruz Foundation (Fiocruz), was “extremely important” for controlling cases and reducing deaths from Covid-19 in the country and abroad. world.
On Thursday, Anvisa also clarified that none of the vaccines against Covid-19 approved by the regulatory agency has been prohibited or unauthorized.
“About the Oxford-AstraZeneca vaccine, it is important to clarify that the vaccine is registered in Brazil. As a result, it is authorized for use in the country under the conditions and indications approved by Anvisa”, he said.
“With the emergence of variants, with technological evolution and with the advancement of knowledge about the disease, it is perfectly normal that some of the first generation vaccines previously applied are replaced by other immunizers, as happens with other regularly updated vaccines”, completes the note
Open
According to Anvisa, the role of the agency is to analyze the requests submitted by pharmaceutical companies, in order to verify that the data and technical information guarantee the efficacy, safety and quality of vaccines and any other medicine authorized in the country.
“As part of the post-use monitoring of the vaccine in Brazil, Anvisa requested, in April 2021, the amendment of the Oxford-AstraZeneca vaccine leaflet to include in the item ‘warning and precautions’ about possible thromboembolic occurrences with thrombocytopenia. All events known adverse events are indicated on the package leaflet,” he said.
Copyright © Estadão. All rights reserved.
#AstraZeneca #vaccine #Brazil #ministry #News